1-9 of 9
Maya Latimer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Yoon Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane
Journal: Blood
Blood (2022) 140 (Supplement 1): 9413–9415.
https://doi.org/10.1182/blood-2022-156782
Published: 2022
Journal Articles

Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study

Kenneth JC Lim, Pietro Di Ciaccio, Nada Hamad, Mark N. Polizzotto, Sam Milliken, Tara Cochrane, Zhong Goh, Briony Shaw, Evelyn Perry, Michael Gilbertson, William Kermode, Chan Yoon Cheah, Maya Latimer, Matthew Ku
Journal: Blood
Blood (2021) 138 (Supplement 1): 1456.
https://doi.org/10.1182/blood-2021-144817
Published: 2021
Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Michelle Poon, Erin Paul, Matthew Ku, Mark Wong, Ashley Beekman, Michael Krigstein, Pietro R Di Ciaccio, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Maya Latimer, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Tara Cochrane, Eliza Hawkes, Chan Yoon Cheah, Stephen Opat, Gareth P Gregory
Journal: Blood
Blood (2021) 138 (Supplement 1): 2532.
https://doi.org/10.1182/blood-2021-145959
Published: 2021
Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, MBBS, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Kirk L Morris, MBBA, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Simon He, MBBS, FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Stephen B Ting, MBBS, FRACP, FRCPA, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Sam Yuen, MBBS, FRACP, FRCPA, James D'Rozario, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, John Taper, MBBS, FRACP, FRCPA, B Pharm, Gavin Cull, MBBS, MD FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Emma Verner, MBBS, FRACP, FRCPA, Uwe H Hahn, MBBS, MD FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Harry Iland, MBBS, FRACP, FRCPA, MHGSA, Nichloas Murphy, MBBS, FRACP, FRCPA, Sundra Ravanathan, MBBS, FRACP, FRCPA, RCPA, Uyen Nguyen, Doen Ming Ong, MBBS, FRACP, FRCPA, RCPA, Sun Loo, MBBS, FRACP, FRCPA, RCPA, Ing-Soo Tiong, MBBS, FRACP, FRCPA, RCPA, Meaghan Wall, MBBS, FRACP, FRCPA, RCPA, PhD, Natasha S Anstee, PhD, Mark Levis, MD PhD, Michael Murray, PhD DSc, Tristan Rawling, PhD, Joanna Leadbetter, PhD, Ashish Bajel, FRACP, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-137334
Published: 2020
Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2015) 126 (23): 5295.
https://doi.org/10.1182/blood.V126.23.5295.5295
Published: 2015
Journal Articles

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 4695.
https://doi.org/10.1182/blood.V124.21.4695.4695
Published: 2014
Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 3325.
https://doi.org/10.1182/blood.V124.21.3325.3325
Published: 2014
Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP
Journal: Blood
Blood (2012) 120 (21): 436.
https://doi.org/10.1182/blood.V120.21.436.436
Published: 2012